Bausch Health settlement for Xifaxan shores up key franchise, says BMO

Bausch Health settlement for Xifaxan shores up key franchise, says BMO Capital. After Bausch Health () announced a generic Xifaxan settlement with Teva’s (TEVA) Actavis unit, BMO Capital analyst Gary Nachman called it “a very positive outcome” that shores up the durability of one of the company’s key growth franchises. The analyst, who said Bausch’s significant debt load likely remains a cap on the stock, keeps a Market Perform rating on the shares but raised his price target to $24 from $22.
https://thefly.com/landingPageNews.php?id=2789459